Global absence and targeting of protective immune states in severe COVID-19
Top Cited Papers
- 24 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 591 (7848), 124-130
- https://doi.org/10.1038/s41586-021-03234-7
Abstract
Although infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has pleiotropic and systemic effects in some individuals1,2,3, many others experience milder symptoms. Here, to gain a more comprehensive understanding of the distinction between severe and mild phenotypes in the pathology of coronavirus disease 2019 (COVID-19) and its origins, we performed a whole-blood-preserving single-cell analysis protocol to integrate contributions from all major immune cell types of the blood—including neutrophils, monocytes, platelets, lymphocytes and the contents of the serum. Patients with mild COVID-19 exhibit a coordinated pattern of expression of interferon-stimulated genes (ISGs)3 across every cell population, whereas these ISG-expressing cells are systemically absent in patients with severe disease. Paradoxically, individuals with severe COVID-19 produce very high titres of anti-SARS-CoV-2 antibodies and have a lower viral load compared to individuals with mild disease. Examination of the serum from patients with severe COVID-19 shows that these patients uniquely produce antibodies that functionally block the production of the ISG-expressing cells associated with mild disease, by activating conserved signalling circuits that dampen cellular responses to interferons. Overzealous antibody responses pit the immune system against itself in many patients with COVID-19, and perhaps also in individuals with other viral infections. Our findings reveal potential targets for immunotherapies in patients with severe COVID-19 to re-engage viral defence.Keywords
Other Versions
This publication has 24 references indexed in Scilit:
- Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell CompartmentCell, 2020
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implicationsScience, 2020
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patientsScience, 2020
- Megakaryocyte and Platelet Transcriptomics for Discoveries in Human Health and DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2020
- An immune-cell signature of bacterial sepsisNature Medicine, 2020
- Uncovering axes of variation among single-cell cancer specimensNature Methods, 2020
- Transcriptome Analysis of Reticulated Platelets Reveals a Prothrombotic ProfileThrombosis and Haemostasis, 2019
- Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and SpeciesImmunity, 2019
- Distinct Patterns of IFITM-Mediated Restriction of Filoviruses, SARS Coronavirus, and Influenza A VirusPLoS Pathogens, 2011
- Programmed Anuclear Cell Death Delimits Platelet Life SpanCell, 2007